Kyivstar (Nasdaq: KYIV) acquires Tabletki.ua for $160M to grow e-health

Rhea-AI Filing Summary

VEON Ltd., through its subsidiary Kyivstar Group Ltd., has completed the acquisition of 100% of Ukrainian digital healthcare platform Tabletki.ua for USD 160 million, payable in Ukrainian hryvna in Ukraine.

Tabletki.ua is a leading Ukrainian platform for finding, comparing, and reserving medicines, partnering with more than 14,000 pharmacies and handling an average of 14 million reservations per month in 2025. Bookings through the platform reached gross merchandise value of UAH 45 billion (USD 1.06 billion) in FY2024 and UAH 57.3 billion (USD 1.19 billion) for the twelve months ending September 30, 2025. Based on unaudited management accounts as of September 30, 2025, Tabletki.ua generated EBITDA of USD 24 million and net profit of USD 20 million, implying a price-to-earnings multiple of 8.0x. The business will join Kyivstar’s broader digital ecosystem, which includes the Helsi e-health platform, Uklon, Kyivstar TV and the MyKyivstar super-app, supporting VEON and Kyivstar’s broader plan to invest USD 1 billion in Ukraine between 2023-2027.

Insights

Telecom and digital services strategist

Profitable healthcare platform acquisition deepens Kyivstar’s digital ecosystem in Ukraine.

Kyivstar has acquired 100% of Tabletki.ua for USD 160 million, adding a scaled, transaction-driven healthcare platform. Tabletki.ua handled about 14 million monthly reservations in 2025 and reached GMV of UAH 57.3 billion (USD 1.19 billion) in the twelve months ending September 30, 2025.

Based on unaudited management accounts as of September 30, 2025, Tabletki.ua delivered EBITDA of USD 24 million and net profit of USD 20 million, implying an 8.0x price-to-earnings multiple. For a digital asset with strong usage metrics, this valuation may appear disciplined, though actual accretion for VEON depends on integration and future performance.

The deal complements Kyivstar’s earlier Helsi acquisition and other digital services, reinforcing its positioning in Ukrainian e-health and consumer digital platforms. Future company communications and financial reports will clarify how Tabletki.ua’s profitability and growth trends contribute to VEON’s consolidated results following closing.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the month of February 2026

Commission File Number 1-34694

VEON Ltd.

(Translation of registrant’s name into English)

Index Tower (East Tower), Unit 1703, Dubai (DIFC), United Arab Emirates

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T

Rule 101(b)(1): o.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T

Rule 101(b)(7): o.

Information contained in this report

On February 10, 2026, the Registrant issued a press release, a copy of which is furnished hereto as Exhibits 99.1.

EXHIBIT INDEX

Exhibit No.			Description of Exhibit
99.1			Press Release, dated February 10, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			VEON LTD.
			(Registrant)
Date: February 11, 2026
			By:			/s/ Sebastian Rice
			Name:			Sebastian Rice
			Title:			Group General Counsel

VEON’s Kyivstar Expands Digital Healthcare Services in Ukraine with Tabletki.ua Acquisition Dubai, Kyiv and New York, February 10, 2026 – VEON Ltd. (Nasdaq: VEON) (“VEON”), a global digital operator, announces that today its subsidiary Kyivstar Group Ltd. (“Kyivstar”) (Nasdaq: KYIV; KYIVW) signed a definitive agreement and completed the transaction to acquire 100% of Tabletki.ua for USD 160 million, payable in Ukrainian hryvna in Ukraine. Tabletki.ua is one of Ukraine’s most widely used digital platforms for finding, comparing and reserving medicines and other products available at Ukrainian pharmacies. Tabletki.ua is trusted by millions of users every month and is Ukraine’s preferred digital platform for accessing prescriptions as well as other medicinal and nutritional health products. The platform enables customers to quickly find, compare, and reserve prescribed and over-the- counter medicines and healthcare products available at pharmacies nationwide, ensuring availability, transparent pricing, and convenient access to essential healthcare products. Tabletki.ua partners with more than 14,000 pharmacies across Ukraine and facilitated an average of 14 million reservations per month in 2025, reflecting its role as an everyday healthcare tool for Ukrainian families. Gross merchandise value (GMV) of bookings via the platform reached UAH 45 billion (USD 1.06 billion) in FY2024 and UAH 57.3 billion (USD 1.19 billion) for the last twelve months ending September 30, 2025. The acquisition strengthens Kyivstar’s growing healthcare ecosystem, complementing its earlier acquisition of the digital healthcare platform Helsi in 2022. Tabletki.ua will become part of Kyivstar’s expanding portfolio of digital services, which also includes ride-hailing and delivery platform Uklon, Kyivstar TV, and the MyKyivstar super-app. “Ukrainian businesses like Tabletki.ua are enabling millions of Ukrainians to benefit from convenient, digital-first solutions, supporting the growth and resilience of the country,” said Oleksander Komarov, President of Kyivstar. “Tabletki.ua already plays an essential role in everyday life for millions of Ukrainians. By combining Kyivstar’s experience in building and scaling digital platforms with Tabletki.ua’s strong market position, we will make healthcare services even more accessible and convenient across Ukraine.” “This acquisition strengthens our commitment to Ukraine by expanding access to digital healthcare solutions that improve everyday life,” said Kaan Terzioglu, VEON Group CEO and Executive Chairman of Kyivstar. “Together, Kyivstar and Tabletki.ua will accelerate the development of innovative, customer-focused healthcare services.”

Based on unaudited management accounts, Tabletki.ua generated LTM EBITDA of USD 24 million and LTM net profit of USD 20 million as of September 30, 2025. The agreed consideration of USD 160 million corresponds to a price to LTM earnings ratio of 8.0X. Today, VEON also published a presentation for investors that provides further information about Tabletki.ua and the strategic rationale for the acquisition. The presentation is available on the VEON website here. About Kyivstar Group Ltd. Kyivstar Group Ltd. (“Kyivstar”) is a Nasdaq-listed holding company that operates JSC Kyivstar, Ukraine’s leading digital operator and the first Ukrainian company to list on a U.S. stock exchange. Kyivstar’s companies provide a broad range of connectivity and digital services, including mobile and fixed-line voice and data, ride-hailing, e-health, digital TV, and enterprise solutions such as Big Data, cloud, and cybersecurity. Together with VEON, Kyivstar intends to invest USD 1 billion in Ukraine between 2023-2027, through investments in infrastructure, technological development and strategic acquisitions, as well as charitable donations for social projects. For more information, please visit https://investors.kyivstar.ua. Nasdaq tickers: KYIV; KYIVW About VEON VEON is a digital operator that provides connectivity and digital services to nearly 150 million connectivity customers and over 140 million digital users. Operating across five countries that are home to more than 6% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ. For more information, visit: www.veon.com. Forward-Looking Statements This release contains “forward-looking statements”, within the meaning of the Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, the closing of Kyivstar’s acquisition of Tabletki.ua, the expected impact of the acquisition for VEON, and the expected financial performance of VEON post the acquisition. There are numerous risks, uncertainties that could cause actual results and performance to differ materially from those expressed by such statements, including risks relating the closing of Kyivstar’s acquisition of Tabletki.ua, the expected impact of the acquisition for VEON, the expected financial performance of VEON post the acquisition, as well as VEON’s ability to achieve anticipated results and business objectives, among others discussed in the section entitled “Risk Factors” in VEON’s 2024 Form 20-F filed with the SEC on April 25, 2025 and other public

filings made by VEON with the SEC. The forward-looking statements contained herein speak only as of the date of this release and VEON disclaims any obligation to update them, except as required by law. VEON disclaims any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law. Additionally, this press release includes certain financial information and data of Tabletki.ua derived from preliminary, unaudited management accounts as of the dates indicated and is subject to completion of customary financial closing, review, and audit procedures. This information is provided for informational purposes only and should not be regarded as a complete statement of financial results or relied upon as necessarily indicative of historical or future performance. Contact Information VEON Hande Asik Chief Communications and Strategy Officer pr@veon.com

FAQ

What acquisition did VEON (VEON) announce involving Kyivstar and Tabletki.ua?

VEON’s subsidiary Kyivstar acquired 100% of Tabletki.ua for USD 160 million, payable in Ukrainian hryvna. Tabletki.ua is a leading Ukrainian digital platform for finding, comparing, and reserving medicines and healthcare products across thousands of partner pharmacies nationwide.

How large is Tabletki.ua’s business according to the VEON (VEON) filing?

Tabletki.ua facilitated an average of 14 million reservations per month in 2025. Gross merchandise value reached UAH 45 billion (USD 1.06 billion) in FY2024 and UAH 57.3 billion (USD 1.19 billion) for the twelve months ending September 30, 2025, highlighting significant transaction volume.

What are Tabletki.ua’s earnings and valuation metrics in the VEON (VEON) disclosure?

Based on unaudited management accounts as of September 30, 2025, Tabletki.ua generated EBITDA of USD 24 million and net profit of USD 20 million. The USD 160 million consideration corresponds to a price-to-earnings ratio of 8.0x, indicating a profit-generating target at acquisition.

How does the Tabletki.ua acquisition fit Kyivstar’s and VEON’s Ukraine strategy?

Tabletki.ua will join Kyivstar’s digital healthcare ecosystem alongside Helsi and other services like Uklon, Kyivstar TV, and MyKyivstar. Together with VEON, Kyivstar plans to invest USD 1 billion in Ukraine between 2023-2027 in infrastructure, technology, acquisitions, and social projects.

What services does Tabletki.ua provide, according to VEON (VEON)?

Tabletki.ua helps users quickly find, compare, and reserve prescription and over-the-counter medicines and healthcare products. Partnering with more than 14,000 pharmacies, it offers transparent pricing, confirmed availability, and convenient nationwide access to essential medicines and nutritional health products.

Where can investors find more information on the Tabletki.ua deal from VEON (VEON)?

VEON has published an investor presentation with additional details on Tabletki.ua and the acquisition’s strategic rationale. The presentation is available on VEON’s website, complementing disclosures in the Form 6-K and associated press release dated February 10, 2026.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 7.8 KB